Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05917210

Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda

This cluster-randomized trial in Uganda will evaluate the effectiveness and implementation of a novel, peer-led TB education and counseling strategy to improve outcomes among persons with tuberculosis (TB) with and without HIV/AIDS and assess the social-behavioral mechanisms underlying the observed treatment effects.

Recruiting

Interested in participating?

Request Info

Key information

About this study

Study Design

Aim 1. The investigators will conduct a parallel, cluster-randomized, hybrid Type 2, effectiveness-implementation trial at 16 sites in Uganda.

This clinical trials registration focuses on Aim 1.

In addition, we will pursue two additional non-interventional aims to better understand the implementation and outcomes of Aim 1:

Aim 2. Within the Aim 1 study, the investigators will also perform a mediation analysis of social and behavioral factors (i.e., TB knowledge, perceived social support, general self-efficacy, HIV/TB stigma) to identify causal mechanisms of impact.

Aim 3. The investigators will conduct nested quantitaive, qualitative, and mixed methods studies to assess the implementation fidelity and context of the peer-navigation strategy for TB-EC, including the following sub-aims:

  • Surveys of peers and healthcare workers to determine the feasibility, acceptability, and appropriateness of the peer-navigation strategy,
  • Direct observations, document review, interviews with peers, and healthcare worker focus groups to characterize fidelity and adaptation of the peer navigation strategy,
  • Measures of implementation costs,
  • In-depth interviews with peer navigators to characterize their experiences,
  • Focus-group discussions (FGDs) with healthcare workers, and
  • In-depth interviews with people with tuberculosis (PWTB) to characterize their experiences.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years
  • Registered as a new, relapse, treatment failure, or previously lost-to-follow-up
  • TB case according to the on-site NTP TB Treatment Register
  • Screened and invited to participate within 30 days of TB treatment initiation

Exclusion criteria

  • Diagnosed with possible or confirmed drug-resistant TB
  • Transferring TB care into the clinic from an off-site facility
  • Residing >40 km from the enrolling clinic
  • Lacking mental capacity to provide informed consent

Treatment and study plan

Peer-Navigaton TB-EC Strategy

Behavioral

Participants receive a peer-navigation strategy for TB education and counseling, including individual-level components such as peer navigator support, an illustrated TB-EC booklet with checklist, individualized adherence planning, and behavior-change messaging; and clinic-level components such as task-sharing with peer navigators, workflow restructuring, community of practice meetings, and implementation champions to support delivery.

Usual TB-EC Strategy

Behavioral

Participants receive usual TB education and counseling delivered by healthcare workers, including individual-level components such as TB-HIV education using a flipchart and use of treatment supporters; and clinic-level components such as routine TB-EC delivery by healthcare workers.

Primary outcomes

  1. Effectiveness: TB Treatment Success

    Time frame: Up to 12 months after TB treatment initiation

    Defined according to criteria from the World Health Organization as either:

    • Treatment completion - completion of TB treatment without evidence of treatment failure as documented in the on-site TB treatment register; or
    • Cure - among participants with microbiologically confirmed TB, a negative smear or culture result in the final month of treatment and on at least one previous occasion.

    The outcome will be assessed as the proportion of participants achieving TB treatment success based on program treatment records.

  2. Effectiveness: Antiretroviral Therapy (ART) Retention

    Time frame: At month 6 after ART initiation (+/- 30 days)

    Among participants living with HIV and initiated on antiretroviral therapy (ART), ART retention will be defined as being (1) alive and (2) receiving ART, as evidenced by a documented ART medication pickup or documented ART supply at a clinical visit recorded in the on-site ART register or on the ART treatment card.

    The outcome will be assessed as the proportion of participants living with HIV who are alive and receiving ART at 6 months after ART initiation.

Secondary outcomes

  1. Implementation: TB Medication Adherence

    Time frame: At month 5 after TB treatment initiation, ±30 days

    Assessed using point-of-care urine colorimetric testing for isoniazid metabolites, conducted by trained on-site research assistants. A positive urine test indicates recent ingestion of isoniazid and will be used as an objective measure of adherence to isoniazid-containing TB therapy.

    The outcome will be assessed as the proportion of participants with a positive urine test for isoniazid metabolites.

  2. Implementation: ART Adherence

    Time frame: At month 5 after TB treatment initiation, ±30 days

    Among participants living with HIV and initiated on antiretroviral therapy (ART), ART adherence will be assessed using point-of-care urine testing for tenofovir using an enzyme-linked immunosorbent assay (ELISA), conducted by trained on-site research assistants. A positive urine test indicates recent ingestion of tenofovir and will be used as an objective measure of adherence to tenofovir-containing ART.

    The outcome will be assessed as the proportion of participants living with HIV and initiated on ART with a positive urine tenofovir assay.

Study contacts

Contact information is provided by the study sponsor or research team.

Achilles Katamba, MBChB, DCH, MS, PhD

CONTACT

[email protected]

J. Lucian Davis, MD, MAS

CONTACT

[email protected]

203-785-2912

Sponsors and collaborators

Lead sponsor

Yale University

Other

Collaborators

  • Makerere University
  • National Institutes of Health (NIH)
  • New York University

Registry information

Acronym: TEACH

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Jun 23, 2023
Registry last updated
Mar 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.